Shares of Constellation Pharmaceuticals (CNST) have lost roughly a quarter of their value since my August 2018 article delved into early clinical evidence for its BET inhibitor CPI-060 in myelofibrosis and other assets of interest. While a small pilot position was suggested, I also stated readers should require strengthening of thesis before adding to their positions in the then recent IPO.
Yesterday, the stock popped up on my radar again after a $65 private financing took place with a number of key institutional investors (including Venrock, Bain Capital and Column Group). ROTY member wellsg pointed